• Abstracts must be submitted online through the abstract submission portal by the submission deadline. No faxed, emailed or mailed abstracts will be accepted.
• There is no fee to submit an abstract.
• Authors do not have to be a member of the sponsoring organizations to submit an abstract. 
• Submissions from international attendees and trainees are welcome and encouraged.
• The submitter does not have to be the primary author.

• Abstract submissions will be considered for lecture and poster presentation during Congress sessions taking place February 6–8, 2025, at the Moscone Center in San Francisco, CA.
• Presenting authors of abstracts accepted for presentation are required to register for and attend the Crohn’s & Colitis Congress to present their abstract at the Moscone Center on the date and time specified in their acceptance invitation.
• All abstract presentations will take place in person at the Moscone Center. Virtual presentations (e.g., pre-recorded videos or live streams) will not be permitted.

• Abstracts containing basic, clinical, or translational research findings in the field of IBD may be submitted.
• Abstracts that have been previously published as an article or full paper at the October 16 submission deadline will not be considered for presentation.
• Abstracts will not be considered for presentation if they have been or will be presented at a national meeting taking place in the United States before the 2025 Crohn’s & Colitis Congress.
• Abstracts that have been presented at national meetings held outside of the U.S. (e.g., APDW, ECCO, UEG Week, etc.) may be submitted.
• Contact info@crohnscolitiscongress.org if you have any questions about abstract eligibility.

When submitting an abstract, authors must select one of the following categories that aligns with their science:

• Adverse Events Related to Therapy
• Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation
• Comparative Effectiveness Studies
• Controlled Clinical Trials in Humans
• Cytokines, Signaling and Receptors
• Diagnostics in IBD
• Diarrheal Disorders, Bacterial Overgrowth, and Food Allergies
• Disease Activity Assessment and Monitoring
• Disease Complications
• Emerging Tools and Technologies and In Vivo Models of GI Diseases
• Epidemiology and Environmental Determinants
• Genetics, Epigenetics, and Gene Function
• Health Care Delivery and Policy (Practice Management Including Telehealth‚ Reimbursement‚ Access to Care)
• Health Care Quality and Delivery
• Health Disparities in Patients with GI Disease
• IBD in Special Populations: Conception, Adolescence, and Older Adults
• Immune Cells in Intestinal Inflammation
• Inflammatory Bowel Disease: Mucosal Innate Function, Host Defense
• Intestinal Inflammation – Cell Signaling, Injury, Repair, and Fibrosis
• Issues of Diversity and Inclusion in GI Healthcare Delivery and Education
• Microbiome Role in Intestinal Inflammation
• Microscopic Colitis, Drug-Induced, and Other Enterocolitides: Clinical
• Natural History and Longitudinal Disease Outcomes
• Neuroimmune Interactions
• Non-Immune Cells in Intestinal Inflammation
• Nutrition and IBD
• Omics for Prognosis, Disease Stratification and Therapy Selection
• Pediatric IBD: Clinical and Translational Studies
• Phase 2 and 3 Microbial Therapies for IBD
• Quality of Life and Psychosocial Outcomes
• Role of Fungi, Viruses and Phages in GI Diseases
• Role of the Gut Microbiome and Pathogens in Immune and Inflammatory Diseases
• Therapeutic Drug Monitoring
• Topics in Global Health (Including Disease Management, Role of Endoscopy, Program Development, Education)
• Translational Application of Intestinal Stem Cells and Organoid Models
• Uncontrolled Therapeutic Observations: Biologics
• Uncontrolled Therapeutic Observations: Non-Biologics

Authors can choose ONE topic only for each individual abstract submitted. If an abstract fits into more than one of the submission categories, the submitter should choose the most appropriate one, as abstracts may be submitted only one time to a single category.

• Abstract titles may not exceed 255 characters, including spaces. Please refrain from using commercial names, institution names, non-standard abbreviations or author names in the title.
• All abstract titles must be capitalized. You will not be able to submit an abstract that contains lowercase letters in the abstract title. The use of superscript, subscript and special characters in abstract titles is permitted.
• There is a limit of 2,900 characters, including spaces, for the abstract text. Information included in images submitted as part of the abstract does not count toward this limit.
• Abbreviations may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases.
• Authors are not required to use headings in their abstracts. If used, however, headings will count toward the 2900 character limit.
• Drug products mentioned in abstracts should be identified by their nonproprietary (i.e., generic) names only.
• Authors may submit up to two images per abstract. Images are not required.
  • Images will only be accepted in .bmp, .gif, .jpg., .png, or .tif file types. PDFs will not be accepted.
  • Images may not exceed 2 GB in size.
  • For assistance taking a screen shot of a Word, Excel or PowerPoint table and saving as an image, follow these instructions on taking a screen shot using Windows or using a Mac.
  • Please format your images appropriately, as images will be published as submitted if accepted for presentation. Be sure to remove any large white borders from images. Large images may be scaled for publication.

• In keeping with ACCME’s Standards for Integrity and Independence, the Congress requires that all individuals in a position to control the educational content of any accredited CE activity disclose all financial relationships with any ineligible company that they have had over the past 24 months.
  • Specifically, all abstract authors are required to list the names of the ineligible companies with which they have relationships and also the roles they played within the named entities (e.g., employee, researcher, shareholder, executive, etc.) over the past 24 months.
  • Authors without relationships may state that they have no information to disclose.
• Authors must submit their financial disclosure at the abstract submission site.
• Author disclosures must be completed prior to abstract submission, so please plan ahead. The submission site will not permit submission of abstracts missing disclosures.
• Submitting authors will be able to send an email to co-authors from the submission site that contains a direct link to their disclosure forms.
  • The message will also include the option to edit their profile and view a proof of the abstract.
  • To send the message, submitters should click the blue “Invite” button next to an author’s name as listed on the Financial Disclosure task.
• At any time, submitters can check the status of their co-authors’ disclosures by logging into the submission site and selecting the Financial Disclosure task.
• If needed, submitting authors also have the option to complete and submit disclosure forms on behalf of their co-authors. By doing so, the submitter agrees to complete the forms to the best of their ability and accepts responsibility for the accuracy of the disclosures.

• The deadline to submit an abstract for consideration for the 2025 meeting is 9 p.m. EDT on Wednesday, October 16, 2024. Absolutely no changes to abstracts or author strings will be permitted after this deadline.
• The submitter certifies that they have the right to submit the abstract and that the data included in the abstract submission and/or presented at the Crohn’s & Colitis Congress is truthful, original, unduplicated and without fraud or fabrication.
• The submitter certifies all authors listed in the submission are investigators with substantial involvement in the study presented in the abstract.
• By submitting an abstract, the submitting author confirms that he or she has permission from all co-authors to include their names in the submission and that all co-authors are aware of and agree to the content of the abstract and support the data contained therein. Submitting authors may, upon request by Congress administration, be asked to provide proof that all authors have given permission for the submission of the abstract and agree on its content.
• The submitter accepts responsibility for the accuracy of the original data and scientific content of the submitted abstract. Please proofread the abstract carefully prior to submission, as edits to the abstract or author string will not be permitted after the October 16 submission deadline.
• The submitter confirms that the submitted abstract is an original paper and has not been or will not be presented at a national meeting taking place in the U.S. prior to the 2025 Crohn’s & Colitis Congress.
• The submitter confirms that the submitted abstract has not been previously published as an article or full paper as of the submission deadline.
• The submitter confirms that the abstract has not been submitted to more than one category or submitted by a co-author.
• The submitter confirms that copyright permissions for all third-party material (including and without limitation textual extracts or illustrations, photographs, maps, diagrams and tables) have been obtained.
• Abstracts that include clinical trial data should follow the CONSORT statement.
• Any human experimentation conducted conforms with the principles of the Declaration of Helsinki of the World Medical Association, and meets all the requirements governing informed consent of the country in which the research was performed.
• Any animal studies should conform with the October 2014 revision of The Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training by the American Physiological Society
• All authors listed on an abstract are required to submit financial disclosure at the abstract submission site by disclosing relationships with ineligible companies by the October 16 submission deadline. The abstract submission site will not permit abstracts missing financial disclosures to be submitted.
• If need be, submitting authors may submit disclosure forms on behalf of their co-authors. By doing so, the submitter accepts full responsibility for the accuracy of their co-author disclosure forms and agrees to complete the forms to the best of their ability.
• By submitting an abstract, the submitter accepts responsibility as the contact person for all correspondence about the abstract and will inform co-authors about its status.
• If an abstract is accepted for presentation at the meeting, the submitting and presenting authors will be sent email communication relevant to presenting abstracts at the meeting, including messages from Congress administration as well as the Congress presentation management and poster vendors.
• Submission of an abstract constitutes a formal commitment by the presenting author to present the abstract in the session and at the time decided upon by the Congress Organizing Committee.
• Presenters are required to register for and attend the 2025 Congress in person. All presentations will take place onsite at the Moscone Center in San Francisco, CA. Virtual presentations will not be accommodated.
• Abstracts may be presented only by authors listed in the author string at the time of submission.
• Any change in the presenting author must be communicated in the form of a written statement to the Congress. Failure to present the abstract for other than well-founded reasons could lead to rejection of abstracts submitted to future Crohn’s & Colitis Congress meetings.
• All presentations will be in English. Oral abstract presentations must be made by an author who speaks and understands English.
• Expenses associated with the submission and presentation of an abstract are the sole responsibility of the presenting author.
• If selected for presentation, the copyright of the abstract is released to the Crohn’s & Colitis Foundation and AGA and permission is given for the abstract to be published online supplements in Gastroenterology and Inflammatory Bowel Diseases in January 2025, as well as on the Congress website, mobile application and/or any other official Congress publications.
• Authors whose abstracts are selected for lecture presentation are advised that Congress sessions may be recorded and made available to in-person and virtual attendees as on-demand video content.

All data presented at Crohn’s & Colitis Congress is embargoed until 8 a.m. PST on the first day of the Congress, Thursday, February 6, 2025.

Abstracts may be made available online to attendees in advance of the Congress for itinerary planning purposes. The embargo policy applies to all abstract data regardless of the date of publication in Congress resources.

Submitted abstracts may be edited any time prior to the submission deadline. To edit an abstract, make the needed changes under the appropriate tasks at the submission site. Edited abstracts must then be saved and resubmitted by the October 16 submission deadline. 

Prior to the October 16 submission deadline, submitters may withdraw submitted abstracts at the submission site. After logging in, submitters should navigate to the abstract task list and then click on the abstract title. Next, using the “Select Status” dropdown, select “Withdrawn.” Finally, click “Save” to withdraw the abstract.

After the submission deadline, the Congress will withdraw abstracts upon written notification to info@crohnscolitiscongress.org from the submitting author by the deadline stated in the notification email. After this date, the Congress cannot guarantee that a withdrawn abstract will be excluded from publication. If circumstances prevent attendance, the presenting author must arrange for the presentation to be given by a co-author. Acceptance of the abstract obligates an author to present the abstract.

1. Read the full abstract submission guidelines.
2. Compose your abstract, ensuring that your abstract adheres to published character count limitations and formatting.
3. Upload up to two images (optional).
4. List all co-authors along with their email addresses and institutions.
5. Review and proof abstract.
6. Ensure all authors complete their disclosures prior to abstract submission.
7. Finalize abstract and submit online by 9 p.m. EDT on Oct. 16, 2024.

For abstract related inquiries, please contact info@crohnscolitiscongress.org